Back to overview

Minority K65R Variants and Early Failure of Antiretroviral Therapy in HIV-1-infected Eritrean Immigrant.

Type of publication Peer-reviewed
Publikationsform Review article (peer-reviewed)
Author Bansal Vineeta, Metzner Karin J, Niederost Barbara, Leemann Christine, Boni Jurg, Gunthard Huldrych F, Fehr Jan S,
Project Minority quasispecies of drug-resistant HIV-1: Emergence, transmission, dynamics, and clinical relevance in acute and chronic HIV-1 infection
Show all

Review article (peer-reviewed)

Journal Emerging infectious diseases
Volume (Issue) 17(10)
Page(s) 1966 - 8
Title of proceedings Emerging infectious diseases
DOI 10.3201/eid1710.110592


To the Editor: Genotypic drug resistance testing before initiation of first-line antiretroviral therapy (ART) is recommended to detect drug-resistant viruses and to avoid treatment failure caused by preexisting drug-resistant viruses (1). However, standard resistance testing cannot detect drug-resistant HIV-1 minority variants unless they represent 20%-25% of the population (2). Approximately 15% of those who underwent seroconversion in the acute phase in industrialized settings harbor drug-resistant HIV-1 minority variants, while standard resistance testing did not detect drug-resistant viruses in those patients (3). We report the case of a treatment-naive HIV-1-infected patient with early treatment failure because of preexisting minority K65R-harboring HIV-1 variants.